Arbutus Biopharma Corp

ABUS remains in a Stage 2 advancing uptrend with rising EMAs supporting demand dominance. A recent shallow pullback into the 9/20 EMA zone held support, offering a favorable entry. Higher highs and higher lows alongside rising volume and RSI affirm medium-term bullish bias. However, overbought conditions and overhead resistance near recent highs pose risks of near-term exhaustion.

• ↑Phase IIa data reveal 33%–67% undetectable HBsAg rates
• ↑$131M cash secures runway through Q4 2026 vs $63–67M burn
• ↓Projected $63–67M cash burn in 2024 risks runway